- Home
- ARBE vs NTHI Comparison
ARBE vs NTHI Comparison
Compare ARBE & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARBE
- NTHI
- Stock Information
- Founded
- ARBE 2015
- NTHI 2008
- Country
- ARBE Israel
- NTHI United States
- Employees
- ARBE N/A
- NTHI N/A
- Industry
- ARBE EDP Services
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- ARBE Technology
- NTHI Health Care
- Exchange
- ARBE Nasdaq
- NTHI Nasdaq
- Market Cap
- ARBE 124.2M
- NTHI 142.5M
- IPO Year
- ARBE N/A
- NTHI N/A
- Fundamental
- Price
- ARBE $1.50
- NTHI $4.26
- Analyst Decision
- ARBE Buy
- NTHI
- Analyst Count
- ARBE 2
- NTHI 0
- Target Price
- ARBE $1.75
- NTHI N/A
- AVG Volume (30 Days)
- ARBE 1.4M
- NTHI 23.3K
- Earning Date
- ARBE 08-05-2025
- NTHI 01-01-0001
- Dividend Yield
- ARBE N/A
- NTHI N/A
- EPS Growth
- ARBE N/A
- NTHI N/A
- EPS
- ARBE N/A
- NTHI N/A
- Revenue
- ARBE $671,000.00
- NTHI $79,990.00
- Revenue This Year
- ARBE $285.16
- NTHI N/A
- Revenue Next Year
- ARBE $370.11
- NTHI N/A
- P/E Ratio
- ARBE N/A
- NTHI N/A
- Revenue Growth
- ARBE N/A
- NTHI 13.52
- 52 Week Low
- ARBE $0.85
- NTHI $4.11
- 52 Week High
- ARBE $5.09
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- ARBE 46.06
- NTHI N/A
- Support Level
- ARBE $1.54
- NTHI N/A
- Resistance Level
- ARBE $1.62
- NTHI N/A
- Average True Range (ATR)
- ARBE 0.10
- NTHI 0.00
- MACD
- ARBE -0.04
- NTHI 0.00
- Stochastic Oscillator
- ARBE 18.42
- NTHI 0.00
About ARBE Arbe Robotics Ltd.
Arbe Robotics Ltd is a provider of 4D Imaging Radar solutions enabling driver-assist systems while paving the way for fully autonomous driving. It is a research and development company in the field of chips for Advanced radar systems, which are mainly intended to be used as Advanced Driver Assistance Systems (ADAS) adapted for autonomous vehicles as well as for non-automotive uses. Its geographical segments include Sweden, China, Germany, USA, and others.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").